Chronic progesterone treatment of male rats with unilateral 6-hydroxydopamine lesion of the dorsal striatum exasperates parkinsonian symptoms

Neuroscience

Volumn 196, Issue , 2011, Pages 228-236

  Chao, O Y ^a   Huston, J P ^a   von Bothmer, A ^a   Pum, M E ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

6 OHDA; Foot slips; Forelimb use; Parkinson's disease; Progesterone; Turning behavior

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; OXIDOPAMINE; PROGESTERONE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FORELIMB; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; SYMPTOMATOLOGY;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROGESTERONE; RATS; RATS, WISTAR;

EID: 80054015303     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.08.043     Document Type: Article

References (79)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Aron L., Klein R. Repairing the parkinsonian brain with neurotrophic factors. Trends Neurosci 2011, 34:88-100.
3. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000, 55:1358-1363.
4. Ballaré C., Uhrig M., Bechtold T., Sancho E., Di Domenico M., Migliaccio A., Auricchio F., Beato M. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 2003, 23:1994-2008.
5. Baron M.S., Wichmann T., Ma D., DeLong M.R. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci 2002, 22:592-599.
6. Baskin Y.K., Dietrich W.D., Green E.J. Two effective behavioral tasks for evaluating sensorimotor dysfunction following traumatic brain injury in mice. J Neurosci Methods 2003, 129:87-93.
7. Baulieu E.E., Schumacher M., Koenig H., Jung-Testas I., Akwa Y. Progesterone as a neurosteroid: actions within the nervous system. Cell Mol Neurobiol 1996, 16:143-154.
8. Boonyaratanakornkit V., Scott M.P., Ribon V., Sherman L., Anderson S.M., Maller J.L., Miller W.T., Edwards D.P. Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 2001, 8:269-280.
9. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009, 30:142-157.
10. Brooks D.J. Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 2008, 4:39-47.
11. Cai W., Zhu Y., Furuya K., Li Z., Sokabe M., Chen L. Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 2008, 55:127-138.
12. Callier S., Morissette M., Grandbois M., Pélaprat D., Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001, 41:131-138.
13. Cavanaugh J.E., Jaumotte J.D., Lakoski J.M., Zigmond M.J. Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under basal conditions and in response to oxidative stress. J Neurosci Res 2006, 84:1367-1375.
14. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
15. de Souza Silva M.A., Topic B., Huston J.P., Mattern C. Intranasal administration of progesterone increases dopaminergic activity in amygdala and neostriatum of male rats. Neuroscience 2008, 157:196-203.
16. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
17. Di Paolo T., Lévesque D., Daigle M. A physiological dose of progesterone affects rat striatum biogenic amine metabolism. Eur J Pharmacol 1986, 125:11-16.
18. Djebaili M., Hoffman S.W., Stein D.G. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004, 123:349-359.
19. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997, 767:340-344.
20. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996, 18:603-606.
21. Ferraz A.C., Matheussi F., Szawka R.E., Rizelio V., Delattre A.M., Rigon P., Hermel Edo E., Xavier L.L., Achaval M., Anselmo-Franci J.A. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem Res 2008, 33:1238-1246.
22. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
23. Giachino C., Galbiati M., Fasolo A., Peretto P., Melcangi R. Neurogenesis in the subependymal layer of the adult rat: a role for neuroactive derivatives of progesterone. Ann N Y Acad Sci 2003, 1007:335-339.
24. Gibson C.L., Murphy S.P. Progesterone enhances functional recovery after middle cerebral artery occlusion in male mice. J Cereb Blood Flow Metab 2004, 24:805-813.
25. Gillies G.E., McArthur S. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm Behav 2010, 57:23-34.
26. Gillies G.E., Murray H.E., Dexter D., McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 2004, 78:513-522.
27. Gonzalez Deniselle M.C., Garay L., Gonzalez S., Saravia F., Labombarda F., Guennoun R., Schumacher M., De Nicola A.F. Progesterone modulates brain-derived neurotrophic factor and choline acetyltransferase in degenerating Wobbler motoneurons. Exp Neurol 2007, 203:406-414.
28. Goss C.W., Hoffman S.W., Stein D.G. Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol Biochem Behav 2003, 76:231-242.
29. Grandbois M., Morissette M., Callier S., Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000, 11:343-346.
30. Ishrat T., Sayeed I., Atif F., Stein D.G. Effects of progesterone administration on infarct volume and functional deficits following permanent focal cerebral ischemia in rats. Brain Res 2009, 1257:94-101.
31. Kirik D., Rosenblad C., Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
32. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Déglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
33. Kulich S.M., Chu C.T. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem 2001, 77:1058-1066.
34. Kurtzke J.F., Goldberg I.D. Parkinsonism death rates by race, sex, and geography. Neurology 1988, 38:1558-1561.
35. Labombarda F., Gonzalez S., Gonzalez Deniselle M.C., Garay L., Guennoun R., Schumacher M., De Nicola A.F. Progesterone increases the expression of myelin basic protein and the number of cells showing NG2 immunostaining in the lesioned spinal cord. J Neurotrauma 2006, 23:181-192.
36. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med 1998, 339:1130-1143.
37. Leonelli E., Bianchi R., Cavaletti G., Caruso D., Crippa D., Garcia-Segura L.M., Lauria G., Magnaghi V., Roglio I., Melcangi R.C. Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. Neuroscience 2007, 144:1293-1304.
38. Lie D.C., Song H., Colamarino S.A., Ming G.L., Gage F.H. Neurogenesis in the adult brain: new strategies for central nervous system diseases. Annu Rev Pharmacol Toxicol 2004, 44:399-421.
39. Lin E., Cavanaugh J.E., Leak R.K., Perez R.G., Zigmond M.J. Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells. J Neurosci Res 2008, 86:108-117.
40. Lindholm P., Voutilainen M.H., Laurén J., Peränen J., Leppänen V.M., Andressoo J.O., Lindahl M., Janhunen S., Kalkkinen N., Timmusk T., Tuominen R.K., Saarma M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007, 448:73-77.
41. Magnaghi V., Veiga S., Ballabio M., Gonzalez L.C., Garcia-Segura L.M., Melcangi R.C. Sex-dimorphic effects of progesterone and its reduced metabolites on gene expression of myelin proteins by rat Schwann cells. J Peripher Nerv Syst 2006, 11:111-118.
42. Marder K., Tang M.X., Mejia H., Alfaro B., CÔté L., Louis E., Groves J., Mayeux R. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996, 47:155-160.
43. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992, 49:492-497.
44. Mehta A., Chesselet M.F. Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Exp Neurol 2005, 193:110-117.
45. Menet V., Prieto M., Privat A., Giménez y Ribotta M. Axonal plasticity and functional recovery after spinal cord injury in mice deficient in both glial fibrillary acidic protein and vimentin genes. Proc Natl Acad Sci U S A 2003, 100:8999-9004.
46. Morissette M., Al Sweidi S., Callier S., Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 2008, 290:60-69.
47. Morissette M., Di Paolo T. Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993, 60:1876-1883.
48. Murphy S.J., Littleton-Kearney M.T., Hurn P.D. Progesterone administration during reperfusion, but not preischemia alone, reduces injury in ovariectomized rats. J Cereb Blood Flow Metab 2002, 22:1181-1188.
49. Murphy S.J., Traystman R.J., Hurn P.D., Duckles S.P. Progesterone exacerbates striatal stroke injury in progesterone-deficient female animals. Stroke 2000, 31:1173-1178.
50. Obeso J.A., Olanow C.W., Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000, 23:S2-S7.
51. Petitclerc M., Bedard P.J., Dipaolo T. Progesterone releases dopamine in male and female rat striatum-a behavioral and microdialysis study. Prog Neuro-Psychopharmacol Biol Psychiatry 1995, 19:491-497.
52. Ramirez A.D., Liu X., Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003, 77:223-231.
53. Roof R.L., Duvdevani R., Braswell L., Stein D.G. Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. Exp Neurol 1994, 129:64-69.
54. Rubin S.M. Parkinson's disease in women. Dis Mon 2007, 53:206-213.
55. Sayeed I., Wali B., Stein D.G. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor Neurol Neurosci 2007, 25:151-159.
56. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
57. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome. Central nervous system diseases: Innovative models of CNS diseases from molecule to therapy 2000, 131-151. Humana Press, Totowa, NJ. D.F. Emerich, R.L. Dean, P.R. Sanberg (Eds.).
58. Schumacher M., Akwa Y., Guennoun R., Robert F., Labombarda F., Desarnaud F., Robel P., De Nicola A.F., Baulieu E.E. Steroid synthesis and metabolism in the nervous system: trophic and protective effects. J Neurocytol 2000, 29:307-326.
59. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., Akwa Y., Rajkowski K., Baulieu E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr Rev 2007, 28:387-439.
60. Schumacher M., Guennoun R., Stein D.G., De Nicola A.F. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007, 116:77-106.
61. Schwarting R.K., Goldenberg R., Steiner H., Fornaguera J., Huston J.P. A video image analyzing system for open-field behavior in the rat focusing on behavioral asymmetries. J Neurosci Methods 1993, 49:199-210.
62. Schwarting R.K., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996, 50:275-331.
63. Shear D.A., Galani R., Hoffman S.W., Stein D.G. Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol 2002, 178:59-67.
64. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., Reynolds I., Klann E., Angiolieri M.R., Johnson J.W., DeFranco D.B. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 2000, 275:12200-12206.
65. Starkey M.L., Barritt A.W., Yip P.K., Davies M., Hamers F.P., McMahon S.B., Bradbury E.J. Assessing behavioural function following a pyramidotomy lesion of the corticospinal tract in adult mice. Exp Neurol 2005, 195:524-539.
66. Thomas A.J., Nockels R.P., Pan H.Q., Shaffrey C.I., Chopp M. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine (Phila Pa 1976) 1999, 24:2134-2138.
67. Tomac A., Lindqvist E., Lin L.F., Ogren S.O., Young D., Hoffer B.J., Olson L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995, 373:335-339.
68. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971, 367:69-93.
69. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157:1015-1022.
70. Voutilainen M.H., Bäck S., Pörsti E., Toppinen L., Lindgren L., Lindholm P., Peränen J., Saarma M., Tuominen R.K. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease. J Neurosci 2009, 29:9651-9659.
71. Walsh S., Finn D.P., Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011, 175:251-261.
72. Woodlee M.T., Asseo-García A.M., Zhao X., Liu S.J., Jones T.A., Schallert T. Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp Neurol 2005, 191:310-317.
73. Woodlee M.T., Kane J.R., Chang J., Cormack L.K., Schallert T. Enhanced function in the good forelimb of hemi-parkinson rats: compensatory adaptation for contralateral postural instability?. Exp Neurol 2008, 211:511-517.
74. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., Patrie J. Are men at greater risk for Parkinson's disease than women?. J Neurol Neurosurg Psychiatry 2004, 75:637-639.
75. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
76. Yamada M., Oligino T., Mata M., Goss J.R., Glorioso J.C., Fink D.J. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci U S A 1999, 96:4078-4083.
77. Yang L., Matthews R.T., Schulz J.B., Klockgether T., Liao A.W., Martinou J.C., Penney J.B., Hyman B.T., Beal M.F. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 1998, 18:8145-8152.
78. Yao X.L., Liu J., Lee E., Ling G.S.F., McCabe J.T. Progesterone differentially regulates pro- and anti-apoptotic gene expression in cerebral cortex following traumatic brain injury in rats. J Neurotrauma 2005, 22:656-668.
79. Yu L., Liao P.C. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J Neural Transm 2000, 107:1139-1147.